BCLI (Brainstorm Cell Therapeutics) Revenue: $0.00 Mil (TTM As of Mar. 2026)


BCLI Brainstorm Cell Therapeutics Inc BCLI
28 GF Score
Price $1.00
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Revenue?

Brainstorm Cell Therapeutics BCLI -7.41% 28 Revenue is $0.00 Mil as of Mar. 2026. GuruFocus rates BCLI with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Brainstorm Cell Therapeutics's revenue for the three months ended in Mar. 2026 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil. Brainstorm Cell Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Brainstorm Cell Therapeutics  (OTCPK:BCLI) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Brainstorm Cell Therapeutics Revenue Related Terms


Brainstorm Cell Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Revenue Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BCLI vs ADAPY, APRE, JSPR: Revenue Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Revenue falls into.


BCLI
28GF Score
Brainstorm Cell Therapeutics Inc BCLI
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
Brainstorm Cell Therapeutics (BCLI) has a Revenue of $0.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Revenue too high?
Brainstorm Cell Therapeutics' current Revenue is $0.00 Mil. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Revenue compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (BCLI) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (BCLI), the current Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for BCLI

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price